SEC For	m 4 FORM	4	UNITED) STAT	ES S			ES AND		NGE C	OMMIS	SION				
					Washington, D.C. 20549							OMB AI			APPRO	VAL
Section 16. Form 4 or Form 5 obligations may continue. See					MT OF CHANGES IN BENEFICIAL OWNER d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							HIP	Estim	OMB Number: 3235-0 Estimated average burden hours per response:		3235-0287 n 0.5
1. Name and Address of Reporting Person [*] Hoey Timothy					2. Issuer Name and Ticker or Trading Symbol <u>Tenaya Therapeutics, Inc.</u> [TNYA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Conflicer (give title Other (specify				
(Last) (First) (Middle) C/O TENAYA THERAPEUTICS, INC. 171 OYSTER POINT BLVD., 5TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 02/15/2022							X below) below) Chief Scientific Officer				
(Street) SOUTH SAN FRANCISCO			94080		4. If Amendment, Date of			of Original Filed (Month/Day/Year)			Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				n
(City) (State) (Zip)																
		Ta	able I - Non	-Deriva	tive S	ecuritie	s A	cquired, Di	isposed o	of, or Bei	neficially	Owned				
Date			2. Transac Date (Month/Da	Execution Date		, Transaction Disposed Code (Instr.		ties Acquired (A) or I Of (D) (Instr. 3, 4 and		5. Amoun Securities Beneficial Owned Fo Reported	s Ily	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	Amount	(A) oi (D)	Price	Transactio (Instr. 3 a				(11501.4)
								quired, Dis s, options,				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Code	Transaction Code (Instr.		er of re ss i (A) sed str. 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to buy)	\$15.19	02/15/2022		A		168,000		03/15/2022 ⁽¹⁾	02/14/2032	Common Stock	168,000	\$0.00	168,0	000	D	

Explanation of Responses:

Display the provided applicable vesting date.

Remarks:

/s/ Jennifer Drimmer Rokovich, 02/17/2022

Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Tenaya Therapeutics, Inc. (the Company), hereby constitutes and appoints Faraz Ali, Leone Patterson and Jennifer Drimmer Rokovich, and each of them, as the true and lawful attorney-in-fact of the undersigned to:

1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the ownership, acquisition or disposition of securities of the Company by the undersigned; and

2. do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the responsibilities of the undersigned to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 14 day of February, 2022.

Signature: /s/ Tim Hoey

Print Name: Tim Hoey